BioCentury

7:00 AM GMT, Aug 22, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

IPX066: Phase III data

Top-line data from the double-blind, crossover, international Phase III ASCEND-PD trial in 84 evaluable patients with advanced PD showed that IPX066 met the primary endpoint of significantly reducing the percentage of "off" time

Read the full 333 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.